CSL312

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hereditary Angioedema

Conditions

Hereditary Angioedema

Trial Timeline

Apr 29, 2021 → Nov 21, 2025

NCT ID

NCT04739059

About CSL312

CSL312 is a phase 3 stage product being developed by CSL for Hereditary Angioedema. The current trial status is completed. This product is registered under clinical trial identifier NCT04739059. Target conditions include Hereditary Angioedema.

What happened to similar drugs?

2 of 20 similar drugs in Hereditary Angioedema were approved

Approved (2) Terminated (0) Active (18)

🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄Canakinumab + PlaceboNovartisPhase 3

🔄EmicizumabRochePhase 3

🔄NitisinoneSwedish Orphan BiovitrumPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07159464	Pre-clinical	Active	—	—	Hereditary Angioedema (HAE)
NCT05819775	Phase 3	Completed	May 30, 2023	Nov 19, 2025	Hereditary Angioedema (HAE)
NCT05306275	Phase 1	Completed	Apr 4, 2022	Sep 27, 2022	Healthy Participants
NCT04739059	Phase 3	Completed	Apr 29, 2021	Nov 21, 2025	Hereditary Angioedema
NCT04580654	Phase 1	Completed	Oct 29, 2020	May 7, 2021	Healthy Volunteers

Competing Products

20 competing products in Hereditary Angioedema

See all competitors

Product	Company	Stage	Hype Score
KVD900	KalVista Pharmaceuticals	Phase 2	29
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 1	23
KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	20
KVD900 + Placebo to KVD900	KalVista Pharmaceuticals	Phase 1	23
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	24
Placebo + KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet	KalVista Pharmaceuticals	Phase 1	23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 2	21
KVD900 600 mg + Drug: KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Deferasirox FCT	Novartis	Phase 2	27
Canakinumab + Placebo	Novartis	Phase 3	40
Ilaris	Novartis	Pre-clinical	33
Standard of Care for Haemophilia A	Roche	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Tafamidis	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Pre-clinical	26
Nitisinone	Swedish Orphan Biovitrum	Pre-clinical	26
Nitisinone	Swedish Orphan Biovitrum	Phase 1	29